1. Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo
- Author
-
Rosemary Huckvale, Alice C. Harnden, Kwai-Ming J. Cheung, Olivier A. Pierrat, Rachel Talbot, Gary M. Box, Alan T. Henley, Alexis K. de Haven Brandon, Albert E. Hallsworth, Michael D. Bright, Hafize Aysin Akpinar, Daniel S. J. Miller, Dalia Tarantino, Sharon Gowan, Angela Hayes, Emma A. Gunnell, Alfie Brennan, Owen A. Davis, Louise D. Johnson, Selby de Klerk, Craig McAndrew, Yann-Vaï Le Bihan, Mirco Meniconi, Rosemary Burke, Vladimir Kirkin, Rob L. M. van Montfort, Florence I. Raynaud, Olivia W. Rossanese, Benjamin R. Bellenie, and Swen Hoelder
- Subjects
Gene Expression Regulation, Neoplastic ,Mice ,Carcinogenesis ,Drug Discovery ,Proto-Oncogene Proteins c-bcl-6 ,Animals ,Humans ,Molecular Medicine - Abstract
The transcriptional repressor BCL6 is an oncogenic driver found to be deregulated in lymphoid malignancies. Herein, we report the optimization of our previously reported benzimidazolone molecular glue-type degrader
- Published
- 2022
- Full Text
- View/download PDF